RA0155

antibody from Oursmab
Targeting: CSF2 GM-CSF, GMCSF
Provider product page for RA0155
Western blot
ELISA
Immunocytochemistry
Flow cytometry
Functional assay

Antibody data

Product number
RA0155 - Provider product page
Provider
Oursmab
Product name
Lenzilumab (Biosimilar Reference Antibody) (CSF2)
Antibody type
Monoclonal
Description
Lenzilumab is a fully human monoclonal antibody that selectively targets and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), a pro-inflammatory cytokine. By binding to GM-CSF, it prevents the cytokine from interacting with its receptor (GM-CSFR) on immune cells, thereby inhibiting the downstream signaling cascade that drives hyperinflammation and cytokine release syndrome (CRS). It has been investigated as a therapeutic agent for conditions characterized by excessive immune activation, most notably in hospitalized patients with COVID-19 pneumonia to prevent or mitigate severe respiratory complications. It is also being explored in other hyperinflammatory and autoimmune contexts, such as acute graft-versus-host disease (aGVHD).
Reactivity
Human
Isotype
IgG
Vial size
100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg
Concentration
Bottled at the concentration indicated on the vial.
Storage
Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.
CSF2 protein structure - RA0155 shown in red.